COPENHAGEN, Feb 20 (Reuters) – Novo Nordisk said on Friday it would nominate Jan van de Winkel and Ramona Sequeira to its board of directors, the first additions since a shake-up at the Danish obesity drugmaker last year.
Novo Nordisk and its majority shareholder, the Novo Nordisk Foundation, in 2025 replaced the drugmaker’s CEO and overhauled the board, installing Lars Rebien Sorensen who also chairs the Foundation, as board chairman, giving him a powerful dual role.
Jan van de Winkel, co-founder and CEO of Genmab, was proposed for election at the annual general meeting to be held on March 26, the Wegovy-maker said in a statement.
Ramona Sequeira acted as President of the Global Portfolio Division of Takeda Pharmaceutical Company Limited from 2022-2025, Novo Nordisk said.
(Reporting by Stine Jacobsen and Louise Rasmussen, editing by Terje Solsvik and Mark Potter)
Comments